Zydus Lifesciences received DCGI approval to initiate two Phase III clinical trials for its novel anti-malarial drug candidate, Zintrodiazine.
The trials will enroll 1,041 patients total to evaluate efficacy and safety against drug-resistant P. falciparum and P. vivax malaria strains.
The development addresses growing artemisinin resistance and is part of a collaboration with Medicines for Malaria Venture (MMV).
Managing Director Dr. Sharvil Patel emphasized the compound's potential to provide an effective alternative to current therapies.